Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution
Recalled by SUN PHARMACEUTICAL INDUSTRIES INC

Class III — least serious
Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
SUN PHARMACEUTICAL INDUSTRIES INC has recalled Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on January 21, 2026 and was initiated on November 26, 2025. It is classified as a Class III recall, which means using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution. The company behind the recall is SUN PHARMACEUTICAL INDUSTRIES INC, based in Princeton, NJ. The FDA describes the product as: “Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution, 60 mL per applicator bottle, Rx only, Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel; Dist. by: Taro Pharmaceuticals USA, Inc., Hawthorne, NY 10532, NDC# 51672-4081-4”
Why was Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution recalled?
According to the FDA, the stated reason for the recall is: “Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.” In plain terms, this recall relates to a chemical impurity.
This recall involves an unwanted chemical detected in the medicine — often a nitrosamine impurity, which regulators limit because long-term exposure above set levels may increase health risks. Regulators recall affected batches as a precaution. Health authorities generally advise talking to a doctor or pharmacist before stopping a prescribed medicine.
What should you do?
If you think you may have bought Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution, compare it against the product description and identifying codes (Lot#: AD30154, AD31143, AD31145, Exp 11/30/2025) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact SUN PHARMACEUTICAL INDUSTRIES INC or your local health authority.
About this recall
This recall was distributed in NJ. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Full recall details
- Status
- Ongoing
- Date reported
- January 21, 2026
- Recall started
- November 26, 2025
- Distributed in
- NJ
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution recalled?+
According to the FDA: Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.
How serious is this recall?+
Class III — least serious. Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
What should I do if I have Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0257-2026. Information last synced from the FDA on July 5, 2026.